Education, Science, Technology, Innovation and Life
Open Access
Sign In
  1. Home
  2. Journals
  3. MEDS Clinical Medicine
  4. Vol 6, Issue 5, 2025

The Expression Levels of Mir-33b-5p and FGFRL1 in Non-Small Cell Lung Cancer Tissues and Their Relationship with Clinical Pathological Features and Prognosis

Download as PDF

DOI: 10.23977/medsc.2025.060514 | Downloads: 3 | Views: 76

Author(s)

Chen Wang 1, Huang Li 2

Affiliation(s)

1 Yueyang Municipal People's Hospital, Yueyang, China
2 Yueyang Hospital of Traditional Chinese Medicine, Yueyang, China

Corresponding Author

Chen Wang

ABSTRACT

This study collected non-small cell lung cancer (NSCLC) tissues and corresponding adjacent non-tumor tissues resected intraoperatively from 92 NSCLC patients admitted between June 2019 and June 2021, aiming to investigate the expression levels of microRNA (miRNA)-33b-5p and fibroblast growth factor receptor-like protein 1 (FGFRL1) in NSCLC tissues, as well as their relationships with clinicopathological features and prognosis. The conclusion we drew is that the expression of miR-33b-5p is significantly decreased and the expression of FGFRL1 is significantly increased in non-small cell lung cancer (NSCLC) tissues. Both are correlated with the clinicopathological features and prognosis of patients, and the combined detection of miR-33b-5p and FGFRL1 can be used to evaluate the prognosis of NSCLC patients.

KEYWORDS

Non-Small Cell Lung Cancer; MicroRNA-33b-5p; Fibroblast Growth Factor Receptor-Like Protein 1; Clinicopathological Features; Prognosis

CITE THIS PAPER

Chen Wang, Huang Li, The Expression Levels of Mir-33b-5p and FGFRL1 in Non-Small Cell Lung Cancer Tissues and Their Relationship with Clinical Pathological Features and Prognosis. MEDS Clinical Medicine (2025) Vol. 6: 96-104. DOI: http://dx.doi.org/10.23977/medsc.2025.060514.

REFERENCES

[1] Liu J, Tian Y, Yi L, et al. High KIF11 expression is associated with poor outcome of NSCLC[J]. Tumori, 2022, 108(1): 40-46.
[2] Srivastava S, Mohanty A, Nam A, et al. Semin Cancer Biol. 2022 Nov;86(Pt 2):233-246. 
[3] Girard N, Basse C. EGFR-mutant NSCLC: monitoring the molecular evolution of tumors in 2022[J]. Expert Rev Anticancer Ther, 2022, 22(10): 1115-1125. 
[4] Das D, Wang J, Hong J. Next-Generation Kinase Inhibitors Targeting Specific Biomarkers in Non-Small Cell Lung Cancer (NSCLC): A Recent Overview[J]. ChemMedChem, 2021, 16(16): 2459-2479. 
[5] Zhang X, Wang S, Wang H, et al. Circular RNA circNRIP1 acts as a microRNA-149-5p sponge to promote gastric cancer progression via the AKT1/mTOR pathway[J]. Mol Cancer, 2019, 18(1): 20-28.
[6] Chang S, Suo D, Zhao Y, et al. Downregulation of lncRNA MCF2L-AS1 Targeting miR-33b-5p Inhibits Gastric Cancer Cell Proliferation, Migration and Invasion, and Promotes Apoptosis [J]. Progress in Modern Biomedicine, 2023, 23(2): 251-257.
[7] Chen R, Li D, Zheng M, et al. FGFRL1 affects chemoresistance of small-cell lung cancer by modulating the PI3K/Akt pathway via ENO1[J]. J Cell Mol Med, 2020, 24(3): 2123-2134.
[8] Guan Lina, Dong Yao, Chen S M, et al. Overexpression of fibroblast growth factor receptor like 1 (FGFRL1) inhibits proliferation and migration of HCT116 human colon cancer cells, and promotes their apoptosis [J]. Chinese Journal of Cellular and Molecular Immunology, 2022, 38(3): 251-256.
[9] Chinese Medical Association, Oncology Society of Chinese Medical Association, Chinese Medical Association Publishing House. Chinese Medical Association guidelines for clinical diagnosis and treatment of lung cancer (Edition 2018) [J]. Chinese Journal of Oncology, 2018, 40(12): 935-964.
[10] Zhao D, Song S S, Li J. Expression levels of SDC3 and miR-33a-5p in cancer tissues of non-small cell lung cancer patients and their clinical diagnostic value [J]. Journal of Tropical Medicine, 2023, 23(7): 914-918.
[11] Tong Y N, Lei J, Tian H, et al. Relationship between the expression levels of miR-1179 and miR-1182 in non-small cell lung cancer tissues and Notch signaling pathway, clinicopathological characteristics and prognosis [J]. Progress in Modern Biomedicine, 2023, 23(22): 4369-4374.
[12] Le X, Nilsson M, Goldman J, Reck M, et al. Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC[J]. J Thorac Oncol, 2021, 16(2): 205- 215. 
[13] Evison M; AstraZeneca UK Limited. The current treatment landscape in the UK for stage III NSCLC[J]. Br J Cancer, 2020, 123(1): 3-9. 
[14] Ma C, Wang X, Yang F, et al. Circular RNA hsa_circ_0004872 inhibits gastric cancer progression via the miR-224/Smad4/ADAR1 successive regulatory circuit[J]. Mol Cancer, 2020, 19(1): 157-164.
[15] Zhang X D, Xie X X, Li J, et al. Application Study of Detection of Serum Exosomal miR-221 and miR-378 Levels in Diagnosis of Gastric Cancer [J]. Journal of Modern Laboratory Medicine, 2020, 35(6): 52-55.
[16] Lin H, Zhao Z, Hao Y, et al. Long noncoding RNA HIF1A-AS2 facilitates cell survival and migration by sponging miR-33b-5p to modulate SIRT6 expression in osteosarcoma. Biochem Cell Biol[J]. 2020, 98(2): 284-292. 
[17] Li S, Yang S, Qiu C, et al. LncRNA MSC-AS1 facilitates lung adenocarcinoma through sponging miR-33b-5p to up-regulate GPAM[J]. Biochem Cell Biol, 2021, 99(2): 241-248.
[18] Liu Q, Huang J, Yan W, et al. FGFR families: biological functions and therapeutic interventions in tumors[J]. MedComm, 2023,4(5):e367.
[19] Sharma P, Kaushik V, Saraya A, et al. Aberrant Expression of FGFRL1 in Esophageal Cancer and Its Regulation by miR-107[J]. Asian Pac J Cancer Prev, 2023, 24(4): 1331-1341. 
[20] Jiang L, Zhang Y, Ren W H. miR-107 inhibits the migration of drug-resistant gastric cancer cells by targeting the FGFRL1/AKT pathway [J]. Chinese Journal of Gerontology, 2023, 43(3): 705-710.
[21] Fan Y, Li H, Yu Z, et al. Long non-coding RNA FGD5-AS1 promotes non-small cell lung cancer cell proliferation through sponging hsa-miR-107 to up-regulate FGFRL1[J]. Biosci Rep, 2020, 40(1): 1-10.

Subscription
E-Mail Alert
Most popular papers
Call for Special Issue
Publication Ethics & OA Statement
Plagiarism Policy
Contact Us
Downloads: 10014
Visits: 672491

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.